Literature DB >> 7621813

Molecular evolution of plasminogen activator inhibitor-1 functional stability.

M B Berkenpas1, D A Lawrence, D Ginsburg.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is a member of the serine protease inhibitor (serpin) supergene family and a central regulatory protein in the blood coagulation system. PAI-1 is unique among serpins in exhibiting distinct active and inactive (latent) conformations in vivo. Though the structure of latent PAI-1 was recently solved, the structure of the short-lived, active form of PAI-1 is not known. In order to probe the structural basis for this unique conformational change, a randomly mutated recombinant PAI-1 expression library was constructed in bacteriophage and screened for increased functional stability. Fourteen unique clones were selected, and shown to exhibit functional half-lives (T1/2S) exceeding that of wild-type PAI-1 by up to 72-fold. The most stable variant (T1/2 = 145 h) contained four mutations. Detailed analysis of these four mutations, individually and in combination, demonstrated that the markedly enhanced functional stability of the parent compound mutant required contributions from all four substitutions, with no individual T1/2 exceeding 6.6 h. The functional stability of at least eight of the remaining 13 compound mutants also required interactions between two or more amino acid substitutions, with no single variant increasing the T1/2 by > 10-fold. The nature of the identified mutations implies that the unique instability of the PAI-1 active conformation evolved through global changes in protein packing and suggest a selective advantage for transient inhibitor function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7621813      PMCID: PMC394356          DOI: 10.1002/j.1460-2075.1995.tb07299.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  36 in total

1.  Co-opting a blind watchmaker.

Authors:  F Flam
Journal:  Science       Date:  1994-08-19       Impact factor: 47.728

Review 2.  What do dysfunctional serpins tell us about molecular mobility and disease?

Authors:  P E Stein; R W Carrell
Journal:  Nat Struct Biol       Date:  1995-02

Review 3.  The serpin superfamily of proteinase inhibitors: structure, function, and regulation.

Authors:  J Potempa; E Korzus; J Travis
Journal:  J Biol Chem       Date:  1994-06-10       Impact factor: 5.157

4.  A relationship between protein stability and protein function.

Authors:  B K Shoichet; W A Baase; R Kuroki; B W Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

5.  Tumour biology. Membrane proteases in focus.

Authors:  J D Vassalli; M S Pepper
Journal:  Nature       Date:  1994-07-07       Impact factor: 49.962

6.  Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition.

Authors:  D A Lawrence; S T Olson; S Palaniappan; D Ginsburg
Journal:  J Biol Chem       Date:  1994-11-04       Impact factor: 5.157

7.  Biological implications of a 3 A structure of dimeric antithrombin.

Authors:  R W Carrell; P E Stein; G Fermi; M R Wardell
Journal:  Structure       Date:  1994-04-15       Impact factor: 5.006

8.  Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.

Authors:  P M Sherman; D A Lawrence; I M Verhamme; D Paielli; J D Shore; D Ginsburg
Journal:  J Biol Chem       Date:  1995-04-21       Impact factor: 5.157

9.  The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions.

Authors:  H A Schreuder; B de Boer; R Dijkema; J Mulders; H J Theunissen; P D Grootenhuis; W G Hol
Journal:  Nat Struct Biol       Date:  1994-01

10.  Three novel missense mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis.

Authors:  D S Millar; A I Wacey; J Ribando; E Melissari; B Laursen; P Woods; V V Kakkar; D N Cooper
Journal:  Hum Genet       Date:  1994-11       Impact factor: 4.132

View more
  71 in total

1.  Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease.

Authors:  P R Elliott; X Y Pei; T R Dafforn; D A Lomas
Journal:  Protein Sci       Date:  2000-07       Impact factor: 6.725

2.  Extending the capabilities of targeted molecular dynamics: simulation of a large conformational transition in plasminogen activator inhibitor 1.

Authors:  P Krüger; S Verheyden; P J Declerck; Y Engelborghs
Journal:  Protein Sci       Date:  2001-04       Impact factor: 6.725

Review 3.  How do proteins avoid becoming too stable? Biophysical studies into metastable proteins.

Authors:  Lisa D Cabrita; Stephen P Bottomley
Journal:  Eur Biophys J       Date:  2003-09-19       Impact factor: 1.733

4.  Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts.

Authors:  Jianyong Zhong; Hai-Chun Yang; Valentina Kon; Agnes B Fogo; Daniel A Lawrence; Ji Ma
Journal:  Lab Invest       Date:  2014-03-31       Impact factor: 5.662

5.  A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Authors:  Evelyn C Nieves; Naveen Manchanda
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

6.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.

Authors:  Lawrence C Thompson; Sumit Goswami; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

7.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.

Authors:  Lawrence C Thompson; Sumit Goswami; David S Ginsberg; Duane E Day; Ingrid M Verhamme; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

8.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

Authors:  D A Waltz; L R Natkin; R M Fujita; Y Wei; H A Chapman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

9.  High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling.

Authors:  Jan K Jensen; Peter G W Gettins
Journal:  Protein Sci       Date:  2008-08-25       Impact factor: 6.725

10.  The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1.

Authors:  Yu-Ran Na; Hana Im
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.